Summary:
Moderna Therapeutics, Inc., mRNA-1010-P304, A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age.
Qualified Participants Must:
• Must be over 65 years of age and not have had their flu shot this season
Qualified Participants May Receive:
- 2-3 visits
- No cost to you
- Compensation for your time and travel is up to $550